C57BL/6JCya-Cfhem1flox/Cya
Common Name:
Cfh-flox
Product ID:
S-CKO-01705
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Cfh-flox
Strain ID
CKOCMP-12628-Cfh-B6J-VA
Gene Name
Product ID
S-CKO-01705
Gene Alias
Mud-1; NOM; Sas-1; Sas1
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
1
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Cfhem1flox/Cya mice (Catalog S-CKO-01705) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000111976
NCBI RefSeq
NM_009888
Target Region
Exon 2~3
Size of Effective Region
~1.5 kb
Detailed Document
Overview of Gene Research
Cfh, or complement factor H, is a complement inhibitor present as a soluble protein and attached to cell surfaces. It is a key player in complement homeostasis, mainly inhibiting excessive activation of the alternative complement pathway [2].
In early-onset macular drusen (EOMD), a novel CFH variant (c.351-2A>G) led to loss of CFH and FHL-1 expression, increased local complement activity, and MAC deposition in EOMD iPSC-derived RPE cells. Nuclease technology correction restored CFH/FHL-1 expression and mitigated alternative pathway complement activity, suggesting CFH haploinsufficiency in EOMD pathogenesis [1]. In a mouse model of atherosclerosis, CFH deficiency limited plaque necrosis in a C3-dependent manner. Deletion of CFH in monocyte-derived inflammatory macrophages increased uncontrolled cell-autonomous C3 consumption, heightened efferocytotic capacity, and reduced plaque size, indicating CFH's role in controlling intracellular C3 levels of macrophages [3].
In conclusion, Cfh plays a crucial role in regulating the alternative complement pathway. Gene-editing models, such as Nuclease technology in EOMD iPSC-derived RPE cells and CFH-deficient mouse models in atherosclerosis, have revealed its significance in macular-related diseases and atherosclerosis. These models help understand the role of Cfh in disease-related biological processes, providing insights for disease-specific research and potential treatment strategies.
References:
1. Lim, Rayne R, Shirali, Sharlene, Rowlan, Jessica, Neitz, Maureen, Chao, Jennifer R. . CFH Haploinsufficiency and Complement Alterations in Early-Onset Macular Degeneration. In Investigative ophthalmology & visual science, 65, 43. doi:10.1167/iovs.65.4.43. https://pubmed.ncbi.nlm.nih.gov/38683564/
2. Boon, Camiel J F, van de Kar, Nicole C, Klevering, B Jeroen, Daha, Mohamed R, den Hollander, Anneke I. 2009. The spectrum of phenotypes caused by variants in the CFH gene. In Molecular immunology, 46, 1573-94. doi:10.1016/j.molimm.2009.02.013. https://pubmed.ncbi.nlm.nih.gov/19297022/
3. Kiss, Máté G, Papac-Miličević, Nikolina, Porsch, Florentina, Mallat, Ziad, Binder, Christoph J. 2023. Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis. In Immunity, 56, 1809-1824.e10. doi:10.1016/j.immuni.2023.06.026. https://pubmed.ncbi.nlm.nih.gov/37499656/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen